Sign inJoin waitlistJoin the waitlist

SD

Sandra D'Angelo

Chief Resident, Internal Medicine

Credentials: · ·

History

Medical Oncology
2026–Present
New York Presbyterian Hospital
Chief Resident2026–Present
2023–2026
SUNY Downstate College of Medicine
2000–2004

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,197 citations
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,203 citations

WT
William Tap
63 papers
MD
Mark Dickson
46 papers
Mrinal Gounder
43 papers
MK
Mary Keohan
40 papers
PC
Ping Chi
35 papers
CA
Cristina Antonescu
34 papers
ER
Evan Rosenbaum
29 papers · 4 as a fellow
Samuel Singer
29 papers · 2 as a fellow
CK
Ciara Kelly
27 papers
Sujana Movva
24 papers
AC
Aimee Crago
18 papers
Gary Schwartz
18 papers

Grants

Identifying Senescence and Immune Biomarkers Predictive of Benefit to Combined CDK4 and Checkpoint Blockade Inhibition in Patients with Dedifferentiated Liposarcoma
Food and Drug Administration · R01
Contact PI · $2.1M · Sloan-Kettering Inst Can Research
2022–2027

Clinical trials

A Study of Ivonescimab in People With Leiomyosarcoma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2026–2029
A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy
Principal investigator · Enrolling by invitation
Memorial Sloan Kettering Cancer Center
2023–2028
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2023–2027
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Principal investigator · Recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2020–2027